These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25278449)

  • 1. Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration- and taxane-resistant prostate cancer.
    Liu SV; Tsao-Wei DD; Xiong S; Groshen S; Dorff TB; Quinn DI; Tai YC; Engel J; Hawes D; Schally AV; Pinski JK
    Clin Cancer Res; 2014 Dec; 20(24):6277-83. PubMed ID: 25278449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer.
    Yu SS; Athreya K; Liu SV; Schally AV; Tsao-Wei D; Groshen S; Quinn DI; Dorff TB; Xiong S; Engel J; Pinski J
    Clin Genitourin Cancer; 2017 Dec; 15(6):742-749. PubMed ID: 28668277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
    Engel J; Emons G; Pinski J; Schally AV
    Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5).
    Emons G; Gorchev G; Sehouli J; Wimberger P; Stähle A; Hanker L; Hilpert F; Sindermann H; Gründker C; Harter P
    Gynecol Oncol; 2014 Jun; 133(3):427-32. PubMed ID: 24713545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels.
    Popovics P; Schally AV; Szalontay L; Block NL; Rick FG
    Oncotarget; 2014 Jun; 5(12):4567-78. PubMed ID: 24994120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5).
    Emons G; Gorchev G; Harter P; Wimberger P; Stähle A; Hanker L; Hilpert F; Beckmann MW; Dall P; Gründker C; Sindermann H; Sehouli J
    Int J Gynecol Cancer; 2014 Feb; 24(2):260-5. PubMed ID: 24418927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors.
    Emons G; Kaufmann M; Gorchev G; Tsekova V; Gründker C; Günthert AR; Hanker LC; Velikova M; Sindermann H; Engel J; Schally AV
    Gynecol Oncol; 2010 Dec; 119(3):457-61. PubMed ID: 20828803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
    Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
    BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone-releasing hormone analog (AN-152).
    Oláh G; Dobos N; Vámosi G; Szabó Z; Sipos É; Fodor K; Harda K; Schally AV; Halmos G
    Eur J Pharm Sci; 2018 Oct; 123():371-376. PubMed ID: 30076951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of Peptide Cytotoxins to LHRH Receptors For Treatment of Cancer.
    Engel JB; Tinneberg HR; Rick FG; Berkes E; Schally AV
    Curr Drug Targets; 2016; 17(5):488-94. PubMed ID: 26951061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers.
    Gründker C; Ernst J; Reutter MD; Ghadimi BM; Emons G
    Oncol Rep; 2011 Sep; 26(3):629-35. PubMed ID: 21667032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH).
    Engel JB; Schally AV; Buchholz S; Seitz S; Emons G; Ortmann O
    Arch Gynecol Obstet; 2012 Aug; 286(2):437-42. PubMed ID: 22555802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
    Föst C; Duwe F; Hellriegel M; Schweyer S; Emons G; Gründker C
    Oncol Rep; 2011 May; 25(5):1481-7. PubMed ID: 21331448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer.
    Tolcher AW; Quinn DI; Ferrari A; Ahmann F; Giaccone G; Drake T; Keating A; de Bono JS
    Ann Oncol; 2012 Apr; 23(4):968-73. PubMed ID: 21859898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer.
    Dorff TB; Tsao-Wei DD; Groshen S; Boswell W; Goldkorn A; Xiong S; Quinn DI; Pinski JK
    Clin Genitourin Cancer; 2013 Dec; 11(4):416-22. PubMed ID: 24099865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Outcomes of
    Barber TW; Singh A; Kulkarni HR; Niepsch K; Billah B; Baum RP
    J Nucl Med; 2019 Jul; 60(7):955-962. PubMed ID: 30683770
    [No Abstract]   [Full Text] [Related]  

  • 17. Somatostatin analogs and disease control in castration-resistant prostate cancer: different biological behavior? Case series and review of the literature.
    D'Angelillo RM; Greco C; Fiore M; Ippolito E; Eolo Trodella L; Iurato A; Molfese E; Ramella S; Trodella L
    Tumori; 2014; 100(3):249-53. PubMed ID: 25076233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.
    Corn PG; Heath EI; Zurita A; Ramesh N; Xiao L; Sei E; Li-Ning-Tapia E; Tu SM; Subudhi SK; Wang J; Wang X; Efstathiou E; Thompson TC; Troncoso P; Navin N; Logothetis CJ; Aparicio AM
    Lancet Oncol; 2019 Oct; 20(10):1432-1443. PubMed ID: 31515154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108.
    Szepeshazi K; Schally AV; Block NL; Halmos G; Nadji M; Szalontay L; Vidaurre I; Abi-Chaker A; Rick FG
    Oncotarget; 2013 May; 4(5):751-60. PubMed ID: 23744510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152.
    Emons G; Sindermann H; Engel J; Schally AV; Gründker C
    Neuroendocrinology; 2009; 90(1):15-8. PubMed ID: 19521066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.